[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein",
    "summary": "Bernstein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $441 from $506 and keeps a Market Perform rating on the shares. The firm thinks suzetrigine is at least somewhat active in diabetic peripheral neuropathy based on the prior small fiber neuropathy trial of VX-150, but probably no better than what has been seen in recent Lyrica trials, and those trials have shown fairly modest delta vs. placebo, the analyst tells investors in a research note. If the firm can’t get reason",
    "url": "https://finnhub.io/api/news?id=41b899b508fcadf3e70a9646d82e3148b7c75d3a9630c9264f1d3587b1b1e44f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734784225,
      "headline": "Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein",
      "id": 132098059,
      "image": "https://media.zenfs.com/en/tipranks_452/d622151edd421d0d1465b02718e80caa",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Bernstein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $441 from $506 and keeps a Market Perform rating on the shares. The firm thinks suzetrigine is at least somewhat active in diabetic peripheral neuropathy based on the prior small fiber neuropathy trial of VX-150, but probably no better than what has been seen in recent Lyrica trials, and those trials have shown fairly modest delta vs. placebo, the analyst tells investors in a research note. If the firm can’t get reason",
      "url": "https://finnhub.io/api/news?id=41b899b508fcadf3e70a9646d82e3148b7c75d3a9630c9264f1d3587b1b1e44f"
    }
  },
  {
    "ts": null,
    "headline": "3 Fantastic Stocks That Could Enjoy a Santa Claus Rally",
    "summary": "Santa Claus will soon be on his way delivering presents to kids around the world.  Three Motley Fool contributors think they've identified fantastic stocks that could be in a good position to benefit from a Santa Claus rally.  Here's why they chose AbbVie (NYSE: ABBV), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX).",
    "url": "https://finnhub.io/api/news?id=c85edc7e6a3998a41c0e4e7c088a85b37e7ed01fa13441b5717ab51bff545cff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734781680,
      "headline": "3 Fantastic Stocks That Could Enjoy a Santa Claus Rally",
      "id": 132093791,
      "image": "https://g.foolcdn.com/editorial/images/801623/santa-claus-buggy-chart.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Santa Claus will soon be on his way delivering presents to kids around the world.  Three Motley Fool contributors think they've identified fantastic stocks that could be in a good position to benefit from a Santa Claus rally.  Here's why they chose AbbVie (NYSE: ABBV), Novo Nordisk (NYSE: NVO), and Vertex Pharmaceuticals (NASDAQ: VRTX).",
      "url": "https://finnhub.io/api/news?id=c85edc7e6a3998a41c0e4e7c088a85b37e7ed01fa13441b5717ab51bff545cff"
    }
  },
  {
    "ts": null,
    "headline": "My Top 10 Stocks to Buy for 2025",
    "summary": "Most of these stocks have a solid earnings track record (except for the clinical-stage biotech that doesn't yet generate product revenue).  A key catalyst is unfolding right now: This top artificial intelligence (AI) chip designer is ramping production of its Blackwell architecture, and demand is \"staggering,\" the company has said.  Nvidia's commitment to innovation should keep it ahead of rivals, making the stock looked reasonably priced today at 43x forward earnings estimates.",
    "url": "https://finnhub.io/api/news?id=a8d105624d7dc9b8a3e61a846be3a8c127bb3234d0da9023e8414c9b5e6873e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734771900,
      "headline": "My Top 10 Stocks to Buy for 2025",
      "id": 132090473,
      "image": "https://g.foolcdn.com/editorial/images/801386/gettyimages-1070239362.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Most of these stocks have a solid earnings track record (except for the clinical-stage biotech that doesn't yet generate product revenue).  A key catalyst is unfolding right now: This top artificial intelligence (AI) chip designer is ramping production of its Blackwell architecture, and demand is \"staggering,\" the company has said.  Nvidia's commitment to innovation should keep it ahead of rivals, making the stock looked reasonably priced today at 43x forward earnings estimates.",
      "url": "https://finnhub.io/api/news?id=a8d105624d7dc9b8a3e61a846be3a8c127bb3234d0da9023e8414c9b5e6873e6"
    }
  },
  {
    "ts": null,
    "headline": "What Moved Markets This Week",
    "summary": "Wall Street suffered its worst weekly loss in over a month on Friday on Fed comments after another rate cut. Read more about this week's major events on Wall Street.",
    "url": "https://finnhub.io/api/news?id=3da869743e802bd8b73bcabd51e34f28d0e7cf941df870dbfc46ac6443ec1f95",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734762785,
      "headline": "What Moved Markets This Week",
      "id": 132093213,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1356756815/image_1356756815.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Wall Street suffered its worst weekly loss in over a month on Friday on Fed comments after another rate cut. Read more about this week's major events on Wall Street.",
      "url": "https://finnhub.io/api/news?id=3da869743e802bd8b73bcabd51e34f28d0e7cf941df870dbfc46ac6443ec1f95"
    }
  }
]